Washington Capital Management Inc Biomarin Pharmaceutical Inc Transaction History

Washington Capital Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Sep 18, 2023	SELL	$80.93 - $108.63 $137,581 - $184,671	-1,700 Reduced 20.73%	6,500 $672,000
Q3 2021 Sep 18, 2023	BUY	$74.77 - $85.47 $613,114 - $700,854	8,200 New	8,200 $633,000
Q3 2020 Nov 05, 2020	BUY	$71.87 - $131.03 $122,179 - $222,751	1,700 Added 26.15%	8,200 $624,000
Q4 2019 Feb 07, 2020	BUY	$64.27 - $86.37 $186,383 - $250,473	2,900 Added 80.56%	6,500 $550,000
Q2 2019 Aug 07, 2019	BUY	$80.35 - $93.9 $289,260 - $338,040	3,600 New	3,600 $308,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Washington Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Washington Capital Management Inc with notifications on news.